Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
27,447,348
-
Share change
-
-2,497,747
-
Total reported value
-
$210,249,848
-
Put/Call ratio
-
158%
-
Price per share
-
$7.66
-
Number of holders
-
81
-
Value change
-
-$80,817,276
-
Number of buys
-
46
-
Number of sells
-
51
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q2 2018
As of 30 Jun 2018,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
81 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,447,348 shares.
The largest 10 holders included
TRV GP II, LLC, TRV GP III, LLC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., Redmile Group, LLC, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, Pharmstandard International S.A., and CITADEL ADVISORS LLC.
This page lists
81
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.